Erratum: The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.

Herrington WG., Preiss D., Haynes R., von Eynatten M., Staplin N., Hauske SJ., George JT., Green JB., Landray MJ., Baigent C., Wanner C.

[This corrects the article DOI: 10.1093/ckj/sfy090.].

DOI

10.1093/ckj/sfz009

Type

Journal article

Journal

Clin Kidney J

Publication Date

08/2020

Volume

13

Permalink Original publication